Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case seriesNathalie Forgeard, Bertrand Arnulf, Laurent Pascal et al.|Blood|2023Cited by 52
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORKMurielle Roussel, Arnaud Jaccard, Michelle Pirotte et al.|HemaSphere|2023Cited by 5
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2